Understand the source comparison
Peptides Help with Female Sexual Health: [Mechanism] Comparison
Bremelanotide (PT-141) MC3R/MC4R agonist in hypothalamus. Increases dopamine signaling in arousal circuits Central desire and motivation FDA-approved; two Phase 3 RCTs showing 0.5–0.9 additional satisfying events/month vs placebo Premenopausal women with HSDD
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Bremelanotide (PT-141)
- MC3R/MC4R agonist in hypothalamus. Increases dopamine signaling in arousal circuits
- Central desire and motivation
- FDA-approved; two Phase 3 RCTs showing 0.5–0.9 additional satisfying events/month vs placebo
- Premenopausal women with HSDD and normal hormone levels
- Subcutaneous injection 45 min before activity
- Oxytocin
- Oxytocin receptor activation in amygdala and limbic system. Reduces anxiety, increases bonding
- Arousal and orgasm intensity (secondary to anxiolysis)
- Small RCTs with inconsistent results; effect size modest and variable
- Women with performance anxiety or relationship-related desire concerns
- Intranasal spray 30 min before activity
- Kisspeptin
- GnRH release → LH/FSH cascade → endogenous testosterone/estrogen production
- Upstream hormonal stimulation; limbic activation
- Early-phase trials show fMRI changes; no clinical efficacy trials yet
- Experimental; no defined patient population
- Intravenous infusion (research only)
- Testosterone (off-label)
- Androgen receptor activation. Peripheral and central effects
- Desire, arousal, and genital sensitivity
- Moderate evidence in postmenopausal women; limited data in premenopausal
- Postmenopausal women with low testosterone and HSDD
- Topical cream or transdermal patch
- Local Estrogen
- Estrogen receptor activation in vaginal tissue. Restores thickness and lubrication
- Peripheral symptoms (dryness, pain)
- Strong evidence for atrophic vaginitis; no direct effect on desire
- Women with vaginal atrophy or pain during intercourse
- Vaginal tablet, cream, or ring
- Professional Assessment
- PT-141 is the only peptide with FDA approval for female sexual dysfunction and the strongest clinical evidence for central desire effects. Oxytocin and kisspeptin remain experimental. For postmenopausal women, testosterone may outperform peptides if hormonal deficiency is the primary driver. But peptides avoid metabolic risks associated with exogenous androgens.